|Mr. Henry Sicignano III, MBA||Chief Exec. Officer, Pres and Director||261.3k||N/A||50|
|Mr. John T. Brodfuehrer||Chief Financial Officer and Treasurer||199.97k||N/A||60|
|Mr. Thomas L. James Esq.||VP, Gen. Counsel and Sec.||222.07k||N/A||59|
|Dr. Michael R. Moynihan Ph.D.||VP of R&D||175.72k||N/A||65|
|Dr. Paul J. Rushton Ph.D.||VP of Plant Biotechnology||170.47k||N/A||55|
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The company's products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine. 22nd Century Group, Inc. has a scientific collaboration with the University of Virginia; and a strategic partnership with Anandia Laboratories, Inc. The company was founded in 1998 and is headquartered in Clarence, New York.
22nd Century Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.